BiomX Inc. (PHGE)
| Market Cap | 5.83M -60.5% |
| Revenue (ttm) | n/a |
| Net Income | -36.20M |
| EPS | -22.19 |
| Shares Out | 1.59M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 61,580 |
| Open | 3.710 |
| Previous Close | 3.300 |
| Day's Range | 3.325 - 3.770 |
| 52-Week Range | 1.500 - 14.712 |
| Beta | 1.70 |
| Analysts | Hold |
| Price Target | n/a |
| Earnings Date | May 14, 2026 |
About PHGE
BiomX Inc., a clinical-stage biopharmaceutical company, develops phage-based therapies using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company’s phage-based therapies include fixed cocktail therapy, which involves developing a single product containing a fixed number of selected phages to cover a range of bacterial strains; and personalized therapy, which involves developing a large library of phages from which single optimal phages are personally matche... [Read more]
Financial Performance
Financial StatementsNews
BiomX Obtains Option to Acquire Control of Israeli Laser-Radar Counter-Drone System
The platform delivers ~99% accuracy in real-world deployments across defense and infrastructure; When closed, the transaction value is estimated at approximately $45 million The platform delivers ~99%...
BiomX Adds Former Mossad Deputy to Advisory Board
Dr. Ehud (Udi) Levi brings decades of intelligence experience as Company evaluates expansion into security, defense, and counter-UAS technologies Dr. Ehud (Udi) Levi brings decades of intelligence exp...
BiomX Inc. Received NYSE American Notification Letter Regarding Stockholders' Equity Deficiency
Discloses “Going Concern” Explanatory Paragraph in Auditor's Report Discloses “Going Concern” Explanatory Paragraph in Auditor's Report
BiomX Launches Security Subsidiary in Israel and Will Initially Invest Over $3 million In Its Operations
Initiative marks entry into Israel's rapidly growing autonomous AI defense, firefighting and first response activities Initiative marks entry into Israel's rapidly growing autonomous AI defense, firef...
BiomX CEO Issues Letter to Stockholders
CEO Letter to Stockholders highlights the Company's strategic and financial reset designed to strengthen BiomX in the near term and unlock future growth opportunities DOVER, Del., March 19, 2026 /PRNe...
BiomX Names Michael Oster as Chief Executive Officer, David Rokach Chief Financial Officer to Support Next Phase of Growth
Seasoned financial leaders join BiomX to support strategic execution and advancement of the company DOVER, Del. and NESS ZIONA, Israel, March 9, 2026 /PRNewswire/ -- BiomX Inc. (NYSE American: PHGE), ...
BiomX Issues Statement Regarding Recent Common Stock Trading Activity
NESS ZIONA, Israel, Jan. 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies targe...
BiomX Announces $3.0 Million Private Placement
Proceeds to Support the Company's Assessment of Opportunities to Advance BX011 and Ongoing Evaluation of Strategic Alternatives Proceeds to Support the Company's Assessment of Opportunities to Advance...
BiomX Awaits FDA Clearance To Restart Cystic Fibrosis Trial After Nebulizer Device Review
BiomX Inc. (NYSE: PHGE) on Tuesday announced that the U.S. Food and Drug Administration (FDA) is continuing its evaluation of the nebulizer device used for drug administration in the company's Phase 2...
BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis
The Company continues working with the third-party manufacturer to address recent FDA follow-up information requests which are required to lift the clinical hold concerning the nebulizer device used i...
BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates
Positive FDA feedback confirms clear clinical pathway for BX011 targeting S. aureus in Diabetic Foot Infections, building on Company's prior Phase 2 success
BiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways
BiomX believes that it has fully addressed the FDA's queries related to the third-party nebulizer used to deliver BX004, which are narrow in scope; an additional FDA request for limited technical clar...
BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis
U.S. FDA has placed a clinical hold on the Phase 2b study as it reviews data submitted by BiomX on third-party nebulizer used to deliver BX004; no concerns were raised in the clinical hold notificatio...
BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates
Positive Phase 2 results for BX211 demonstrated >40% wound size reduction vs. placebo in diabetic foot osteomyelitis patients; Planning underway for potential registrational study
BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025
NESS ZIONA, Israel, Aug. 06, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that ...
BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis
First patient dosing in Company's Phase 2b trial marks pivotal milestone in phage therapy development program targeting antibiotic-resistant lung infections in Cystic Fibrosis patients; topline result...
BiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic Fibrosis
Premier research journal article provides validation for BiomX's phage therapy platform, showcasing first-in-human Phase 1b/2a trial results for antibiotic-resistant P. aeruginosa infections New, upda...
BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference
Presentation to Focus on Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO) Presentation to Focus on Positive Topline Results from Phas...
BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates
In March 2025, BiomX announced positive topline results of the phase 2 trial evaluating BX211 for the treatment of diabetic foot osteomyelitis (DFO)
BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025
NESS ZIONA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that t...
BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure
NESS ZIONA, Israel, April 01, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that...
BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)
The Company will host a conference call and webcast today at 9:00 AM ET, followed by a Key Opinion Leader (KOL) event on April 3, 2025, at 11:00 AM ET to discuss the results
BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates
NESS ZIONA, Israel, March 25, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE, the “Company” or “BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that ...
BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
NESS ZIONA, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that...
BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates
BX211 Phase 2 for treatment of Diabetic Foot Osteomyelitis (DFO) patient enrollment completed and on track to report topline results in Q1 2025